Research.Patient.info
Diffuse Cutaneous Systemic Sclerosis (dcSSc) research hub
2 indexed studies · 0 currently recruiting
- authorisedTherapeutic exploratory (Phase II)
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This study tests a new medicine called MTX-474 for adults with diffuse cutaneous systemic sclerosis. This rare condition causes skin thickening and hardening across the body. Researchers want to see if MTX-474 is safe and if it helps soften the skin over 24 weeks compared to a dummy treatment.
Netherlands · Romania · Poland - authorisedPhase I and Phase II (Integrated)- First administration to humans
A single-arm, open-label, multi-centre, phase I/II first-in-human study evaluating the safety and clinical activity of QEL-005, an autologous CAR T-regulatory cell therapy treatment targeting CD19, in patients with diffuse cutaneous systemic sclerosis (dcSSc) and in patients with difficult to treat rheumatoid arthritis (D2TRA).
This study is testing a new cell therapy called QEL-005 for people with specific types of severe rheumatoid arthritis or a skin condition called diffuse cutaneous systemic sclerosis. Researchers want to see if it's safe and if it helps improve these conditions.
Spain · Germany